Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
-Issues related to over the counter drug policy -Issues related to ingredient labeling -H.R. 3749(IH) Health and Endocrine Research on Personal Care Products for Women Act* -H.R.4273 To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter monograph drugs, and for other purposes
Over-the-Counter Monograph Drug User Fee Amendments
Client: THE PROCTER AND GAMBLE COMPANY · Firm: THE PROCTER AND GAMBLE COMPANY
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
THE PROCTER AND GAMBLE COMPANY via THE PROCTER AND GAMBLE COMPANY
2025 · third_quarter · Q3
-H.R.4273: Over-the-Counter Monograph Drug User Fee Amendments (Entire Bill)
-Issues related to IEEPA Reciprocal Tariffs -Issues related to Softwood Lumber 232 Trade Investigation -Issues related to America First Trade Policy -Issues related to tariffs (232 Pharmaceuticals)
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
-Issues related to over the counter drug policy -Issues related to ingredient labeling -H.R. 3749(IH) Health and Endocrine Research on Personal Care Products for Women Act* -H.R.4273 To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter monograph drugs, and for other purposes
Over-the-Counter Monograph Drug User Fee Amendments
Client: THE PROCTER AND GAMBLE COMPANY · Firm: THE PROCTER AND GAMBLE COMPANY
-H.R.4273: Over-the-Counter Monograph Drug User Fee Amendments (Entire Bill)
THE PROCTER AND GAMBLE COMPANY via THE PROCTER AND GAMBLE COMPANY
2025 · second_quarter · Q2
-Issues related to IEEPA Tariffs -Issues related to the Pharmaceuticals Section 232 Trade Investigation -Issues related to Lumber Section 232 Trade Investigation
-Issues related to over the counter drug policy -Issues related to ingredient labeling -H.R. 3749(IH) Health and Endocrine Research on Personal Care Products for Women Act* -H.R.4273 To amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user fee program for over-the-counter monograph drugs, and for other purposes
Filing targets: Commerce, Dept of (DOC), Consumer Product Safety Commission (CPSC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of the Vice President of the United States, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)